



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

21 July 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard ([eugeneb@sun.ac.za](mailto:eugeneb@sun.ac.za)), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally.

### Important notices

- NEWS: [New career development program launched for LMIC scientists](#)
  - [FAQs for applicants to Emerging Global Leader Award](#)
  - [FAQs for applicants to International Research Scientist Development Award \(IRSDA\)](#)
- [NIH Announces Strategy to Improve Reproducibility of Funded Research](#)
- [Don't Lose Your Grant Because of Human Subjects or Animal Welfare Concerns](#)  
Does your summary statement indicate a concern (code 44) about the protection of human subjects or animal welfare in your application?
- [When I submit a progress report, do I need to use the updated biosketch format?](#)
- [Focus on Foreign Investigators: Eligibility Requirements](#)
- Request for Information (RFI): Inviting Comments and Suggestions on the Environmental influences on Child Health Outcomes (ECHO) Program (the National Children's Study Alternative) ([NOT-OD-15-117](#))
- Broad Agency Announcement (BAA): Development of Therapeutic Products for Biodefense and Emerging Infectious Diseases, NIAID-DMID-NIH-AI-2015037 ([NOT-AI-15-048](#))

### 1. Title: Alcohol Use Disorders: Behavioral Treatment, Services and Recovery Research

<b>Letter of Intent due date:</b> 30 days before application due date	<b>Hyperlink:</b> <a href="#">(PA-15-299)</a>	<b>Type:</b> RO1
	<a href="#">(PA-15-301)</a>	R21
	<a href="#">(PA-15-300)</a>	R03

**Application Due Date:** Multiple dates by 5:00 PM local time of applicant organization. See announcements.

**Purpose:** This Funding Opportunity Announcement (FOA) encourages grant applications from institutions/organizations that propose to support research on behavioral treatment for alcohol use disorders; organizational, financial, and management factors that facilitate or inhibit the delivery of services for alcohol use disorders; and phenomenon of recovery from alcohol use disorders.

**Budget:** **RO1:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. **R21:** The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **RO3:** Application budgets are limited to \$50,000 in direct costs per year. The project period may not exceed two years.

### 2. Title: Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research

<b>Letter of Intent due date:</b> 30 days before application due date	<b>Hyperlink:</b> <a href="#">(PAR-15-297)</a>	<b>Type:</b> UO1
---	--	------------------

**Application Due Date:** February 17, 2016; August 16, 2016; February 15, 2017; August 15, 2017; February 15, 2018; August 15, 2018, by 5:00 PM local time of applicant organization.

**Purpose:** This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

**U01 – NIH Research Project Cooperative Agreement:** supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

**R01 – NIH Research Project Grant Program:** most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

**R03 – NIH Small Grant Program:** limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

**R21 – NIH Exploratory/Developmental Research Grant:** encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

**R21/R33 - Phased Innovation:** The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)

**Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University**  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Dr Christa de Vries* • Tel: 9838 • Email: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)